Priority Review Voucher Value Still Confounds, But Remains An Incentive For Sponsors
This article was originally published in The Pink Sheet Daily
As FDA increases the asking price, a survey by non-profit finds companies would expect to invest an average of $100 million to obtain a voucher, but responders gave a wide range of potential amounts.
You may also be interested in...
Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.
Along with adding Ebola to list of disease treatments eligible for tropical disease priority review voucher, bill moving through Congress would cut notification time required before redemption.
Even after paying BioMarin $67.5 million for the voucher itself, the firms still don’t know how much FDA will charge for a chance to get Praluent to market faster.